150322-43-3

150322-43-3 structure

Name: Prasugrel
Chemical Name: Prasugrel
CAS Number: 150322-43-3
Molecular Formula: C₂₀H₂₀FNO₃S
Molecular Weight: 373.44100
Catalog: API Blood system medication Anticoagulant and antiplatelet drugs
Create Date: 2018-05-11 08:00:00
Modify Date: 2024-01-02 15:03:35
Prasugrel is a platelet inhibitor with IC50 value of 1.8 μM.IC50 value:Target: P2Y12 receptorPrasugrel is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI. Prasugrel reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 μm. From Wikipedia

Name	Prasugrel
Synonyms	5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate Prasugrel Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)- Unii-34K66tbt99 Effient Efient

Description	Prasugrel is a platelet inhibitor with IC50 value of 1.8 μM.IC50 value:Target: P2Y12 receptorPrasugrel is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI. Prasugrel reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 μm. From Wikipedia
Related Catalog	Signaling Pathways >> GPCR/G Protein >> P2Y Receptor Research Areas >> Cardiovascular Disease
References	[1]. Pharmacokinetic basis of the antiplatelet action of prasugrel By Schroer, Karsten; Siller-Matula, Jolanta M.; Huber, Kurt From Fundamental & Clinical Pharmacology (2012), 26(1), 39-46. [2]. Selective Blockade of P2Y12 Receptors by Prasugrel Inhibits Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion in Rats By Sugidachi, Atsuhiro; Yamaguchi, Shinji; Jakubowski, Joseph A.; Ohno, Kosaku; Tomizawa, Atsuyuki; Hashimoto, Masami; Niitsu, Yoichi From Journal of Cardiovascular Pharmacology (2011), 58(3), 329-334. [3]. Darius H.Prasugrel.Hamostaseologie. 2012 Aug 1;32(3):186-90. [4]. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. [5]. Spiel AO, Derhaschnig U, Schwameis M, Bartko J, Siller-Matula JM, Jilma B.Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.Clin Sci (Lond). 2012 Nov 1;123(10):591-600.

Density	1.347
Boiling Point	493.5ºC at 760 mmHg
Melting Point	122 °C
Molecular Formula	C₂₀H₂₀FNO₃S
Molecular Weight	373.44100
Flash Point	252.3ºC
Exact Mass	373.11500
PSA	74.85000
LogP	3.82890
Vapour Pressure	0mmHg at 25°C
Index of Refraction	1.619
Storage condition	2-8°C

Hazard Codes	Xi
RIDADR	NONH for all modes of transport

Precursor 9
150322-38-6 952340-38-4 108-24-7 75-36-5
204205-33-4 951380-43-1 952340-39-5 951380-42-0
1100905-46-1
DownStream 0

150322-43-3	1127252-92-9
1189919-49-0	1127253-02-4
389574-20-3	1391194-39-0
1100905-45-0	150322-38-6
947502-66-1	1618107-96-2